These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 18700253)

  • 1. The economics of licensing contracts.
    Mason R; Savva N; Scholtes S
    Nat Biotechnol; 2008 Aug; 26(8):855-7. PubMed ID: 18700253
    [No Abstract]   [Full Text] [Related]  

  • 2. Getting real about valuations in biotech.
    Villiger R; Bogdan B
    Nat Biotechnol; 2005 Apr; 23(4):423-8. PubMed ID: 15815665
    [No Abstract]   [Full Text] [Related]  

  • 3. Value drivers in licensing deals.
    Arnold K; Coia A; Saywell S; Smith T; Minick S; Löffler A
    Nat Biotechnol; 2002 Nov; 20(11):1085-9. PubMed ID: 12410249
    [No Abstract]   [Full Text] [Related]  

  • 4. Survey reveals US university licensing up, startup formation down.
    Bouchie A
    Nat Biotechnol; 2005 Feb; 23(2):261-2. PubMed ID: 15724274
    [No Abstract]   [Full Text] [Related]  

  • 5. [Innovative agreements with the pharmaceutical industry: "pay for performance"].
    Badia X; Prior M
    Farm Hosp; 2010; 34(2):53-5. PubMed ID: 20207566
    [No Abstract]   [Full Text] [Related]  

  • 6. Value creation and sharing among universities, biotechnology and pharma.
    Edwards MG; Murray F; Yu R
    Nat Biotechnol; 2003 Jun; 21(6):618-24. PubMed ID: 12776145
    [No Abstract]   [Full Text] [Related]  

  • 7. Goodbye Columbus! New NRDOs forego discovery.
    Thiel KA
    Nat Biotechnol; 2004 Sep; 22(9):1087-92. PubMed ID: 15340473
    [No Abstract]   [Full Text] [Related]  

  • 8. Evaluation of a pharmaceutical risk-sharing agreement when patients are screened for the probability of success.
    Mahjoub R; Ødegaard F; Zaric GS
    Health Econ; 2018 Jan; 27(1):e15-e25. PubMed ID: 28627808
    [TBL] [Abstract][Full Text] [Related]  

  • 9. When times get tough.
    Jong S
    Nat Biotechnol; 2009 Mar; 27(3):226-8. PubMed ID: 19274868
    [No Abstract]   [Full Text] [Related]  

  • 10. US biodefense contracts continue to lure biotechs.
    Shaffer C
    Nat Biotechnol; 2010 Mar; 28(3):187-8. PubMed ID: 20212465
    [No Abstract]   [Full Text] [Related]  

  • 11. Deal-making trends in oncology.
    Moore K; Walker J
    Nat Rev Drug Discov; 2009 Aug; 8(8):604. PubMed ID: 19644466
    [No Abstract]   [Full Text] [Related]  

  • 12. Navigating biotechnology's new fiscal opportunities.
    Purcell DJ
    Nat Biotechnol; 1998 May; 16 Suppl():51-3. PubMed ID: 9591271
    [No Abstract]   [Full Text] [Related]  

  • 13. Stelios Papadopoulos.
    Papadopoulos S
    Nat Biotechnol; 2011 Mar; 29(3):184. PubMed ID: 21390003
    [No Abstract]   [Full Text] [Related]  

  • 14. Q&A: Horst Domdey.
    Wald C
    Nature; 2016 May; 533(7601):S30-1. PubMed ID: 27144606
    [No Abstract]   [Full Text] [Related]  

  • 15. The service-based bioeconomy.
    Nat Biotechnol; 2014 Jul; 32(7):597. PubMed ID: 25004205
    [No Abstract]   [Full Text] [Related]  

  • 16. Sumitomo buys Oxford finance.
    Bouchie A
    Nat Biotechnol; 2004 Apr; 22(4):480. PubMed ID: 15085808
    [No Abstract]   [Full Text] [Related]  

  • 17. Big pharma wants you.
    Mack GS
    Nat Biotechnol; 2006 Nov; 24(11):1317-9. PubMed ID: 17162751
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In-licensing as a business model.
    Schafer DP
    Nat Biotechnol; 2002 Jul; 20 Suppl():BE36-9. PubMed ID: 12089585
    [No Abstract]   [Full Text] [Related]  

  • 19. Biotech entrepreneurs swoon over proposed fundraising changes.
    Venkataramanan M
    Nat Med; 2012 Jan; 18(1):3. PubMed ID: 22227645
    [No Abstract]   [Full Text] [Related]  

  • 20. Patent threat in emerging economies shifts to biotech.
    Jayaranam K
    Nat Biotechnol; 2008 May; 26(5):481-3. PubMed ID: 18464760
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.